IP Library Patent Application 18512632
Patent Application
App. No. 18/512,632

MICROPARTICLES CONTAINING BUPROPION

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/512,632
Abstract

This disclosure relates to microparticles containing bupropion, e.g., microparticles having a particle diameter of about 50 μm to about 100 μm. These microparticles may be included in pharmaceutical compositions and/or dosage forms for treatment of various disease, such as depression.

Claims (22)

1 . A microparticle comprising bupropion hydrochloride, wherein the microparticle has a particle diameter of about 50 μm to about 100 μm.

2 . The microparticle of claim 1 , wherein the particle diameter is determined by laser diffraction.

3 . The microparticle of claim 1 , wherein the bupropion hydrochloride comprises about 30% to about 35% of the weight of the microparticle.

4 . A dosage form comprising microparticles containing bupropion and dextromethorphan, wherein at least about 80% of the microparticles have a particle diameter of about 1 μm to about 300 μm, and wherein the median microparticle diameter is about 50 μm to about 100 μm.

5 . The dosage form of claim 4 , wherein the particle diameter is determined by laser diffraction.

6 . The dosage form of claim 4 , wherein the median microparticle diameter is about 50 μm to about 100 μm as determined by laser diffraction.

7 . The dosage form of claim 6 , wherein the 10 th percentile of microparticle diameter is about 1 μm to about 30 μm as determined by laser diffraction.

8 . The dosage form of claim 6 , wherein the 90 th percentile of microparticle diameter is about 200 μm to about 300 μm as determined by laser diffraction.

9 . The dosage form of claim 6 , wherein the 90 th percentile of microparticle diameter is about 2 times to about 10 times the median microparticle diameter as determined by laser diffraction.

10 . The dosage form of claim 6 , wherein the median particle diameter is about 2 times to about 50 times the 10 th percentile of microparticle diameter as determined by laser diffraction.

11 . The dosage form of claim 6 , wherein the 90 th percentile of microparticle diameter is about 5 to about 200 times the 10 th percentile of microparticle diameter as determined by laser diffraction.

12 . The dosage form of claim 6 , further comprising microcrystalline cellulose.

13 . A pharmaceutical composition comprising microparticles containing bupropion, wherein at least 80% of the microparticles have a particle diameter of about 1 μm to about 300 μm.

14 . The pharmaceutical composition of claim 13 , wherein the particle diameter is determined by laser diffraction.

15 . The pharmaceutical composition of claim 13 , wherein the microparticles containing bupropion have a median particle diameter of about 50 μm to about 100 μm as determined by laser diffraction.

16 . The pharmaceutical composition of claim 13 , wherein microparticles in the 10 th percentile based upon particle diameter have a diameter of about 1 μm to about 30 μm as determined by laser diffraction.

17 . The pharmaceutical composition of claim 13 , wherein microparticles in the 90 th percentile based upon particle diameter have a diameter of about 200 μm to about 300 μm as determined by laser diffraction.

18 . The pharmaceutical composition of claim 13 , wherein the 90 th percentile of microparticle diameter is about 2 times to about 10 times the median microparticle diameter as determined by laser diffraction.

19 . The pharmaceutical composition of claim 13 , wherein the median particle diameter is about 2 times to about 50 times the 10 th percentile of microparticle diameter as determined by laser diffraction.

20 . The pharmaceutical composition of claim 13 , wherein the 90 th percentile of microparticle diameter is about 5 to about 200 times the 10 th percentile of microparticle diameter as determined by laser diffraction.

21 . The pharmaceutical composition of claim 13 , further comprising a sustained release or controlled release polymer.

22 . The pharmaceutical composition of claim 13 , further comprising magnesium stearate.

Assignments (2)
SECURITY INTEREST Recorded May 9, 2025
From: AXSOME THERAPEUTICS, INC.; AXSOME MALTA LTD.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 071247/0836 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2024
From: TABUTEAU, HERRIOT
To: AXSOME THERAPEUTICS, INC.
Reel/Frame 066068/0065 →